- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 9, 2021
Highlights
- Market Cap
- $2.47M
- Enterprise Value
- $2.47M
- EBITDA (TTM)
- -$8.55M
- Year Range
- $0.06 - $0.90
- ROA (TTM)
- -842.22%
- ROE (TTM)
- 555.00%
- Avg. Volume (1M)
- 493
- Avg. Volume Value (1M)
- $45.33
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NRSNW Performance Chart
NeuroSense Therapeutics Ltd. Warrant (NRSNW) is down 68.9% since the beginning of the year. At $0 per share, NRSNW is trading 89.0% below its 52-week high of $1.
Loading charts...
Compare this symbol against anything
Returns By Period
NeuroSense Therapeutics Ltd. Warrant (NRSNW) has returned -68.91% so far this year and -74.51% over the past 12 months.
NeuroSense Therapeutics Ltd. Warrant
- 1D
- 0.00%
- 1M
- 35.61%
- 6M
- -73.84%
- YTD
- -68.91%
- 1Y
- -74.51%
- 3Y*
- -25.92%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -37.50%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NRSNW Monthly Returns History
Based on dividend-adjusted daily data since Dec 9, 2021, NRSNW's average daily return is +1.45%, while the average monthly return is +5.29%. At this rate, an investment would double in approximately 1.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jan 2024 with a return of +156.1%, while the worst month was Dec 2023 at -68.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NRSNW closed higher 28% of trading days. The best single day was Mar 21, 2022 with a return of +323.3%, while the worst single day was Nov 13, 2024 at -59.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.86% | -45.00% | -4.31% | -0.05% | -63.18% | -14.40% | 57.78% | -68.91% | |||||
| 2025 | -47.73% | -13.04% | 2.65% | 40.04% | 68.35% | 31.06% | -13.30% | 3.64% | -33.33% | -23.26% | 44.00% | -23.86% | -27.34% |
| 2024 | 156.08% | 40.00% | 50.00% | -41.64% | -38.80% | 37.33% | -27.18% | 13.33% | -11.71% | 18.39% | 35.62% | 82.57% | 463.37% |
| 2023 | 78.88% | 80.56% | -25.15% | -10.38% | -28.33% | -5.48% | 3.47% | -34.56% | -3.19% | -28.34% | 125.23% | -68.76% | -51.49% |
| 2022 | -23.42% | -29.99% | 22.94% | -25.27% | -35.84% | 76.60% | -43.58% | -13.17% | 18.05% | -25.46% | 34.23% | -45.45% | -82.38% |
| 2021 | 3.85% | 3.85% |
Benchmark Metrics
NeuroSense Therapeutics Ltd. Warrant has an annualized alpha of 3275.46%, beta of 0.91, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 09, 2021.
- This stock participated in 140.13% of S&P 500 Index downside but only -47.11% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 3,275.46%
- Beta
- 0.91
- R²
- 0.00
- Upside Capture
- -47.11%
- Downside Capture
- 140.13%
Return for Risk
Risk / Return Rank
NRSNW ranks 38 for risk / return — above 38% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for NeuroSense Therapeutics Ltd. Warrant (NRSNW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NRSNW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.69 | ||
| Sortino ratioReturn per unit of downside risk | -0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.25 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | -0.89 | 2.00 | -2.90 |
| Martin ratioReturn relative to average drawdown | -1.25 | 8.49 | -9.74 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeuroSense Therapeutics Ltd. Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeuroSense Therapeutics Ltd. Warrant was 94.78%, occurring on Jul 24, 2026. The portfolio has not yet recovered.
The current NeuroSense Therapeutics Ltd. Warrant drawdown is 91.36%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-94.78%Jul 2026 | 4y 4mo | — | 4y 4moMar 2022 - now | — |
-77.35%Mar 2022 | 3mo 3d | 4d | 3mo 7dDec 2021 - Mar 2022 | Bear market2022 |
-5.94%Dec 2021 | 1d | 3d | 3dDec 2021 - Dec 2021 | — |
Drawdown Indicators
| NRSNW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.78% | -56.78% | -38.00% |
Max Drawdown (1Y)Largest decline over 1 year | -92.00% | -9.10% | -82.90% |
Max Drawdown (3Y)Largest decline over 3 years | -93.26% | -18.90% | -74.36% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -91.36% | -1.58% | -89.78% |
Average DrawdownAverage peak-to-trough decline | -73.65% | -10.70% | -62.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 65.91% | 2.14% | +63.77% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeuroSense Therapeutics Ltd. Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeuroSense Therapeutics Ltd. Warrant is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NRSNW
Add NeuroSense Therapeutics Ltd. Warrant to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NRSNW